Bavarian Nordic is committed to building a pipeline of immunotherapy candidates for major cancers with large unmet medical needs. The Company leverages its viral vaccine platforms to create novel, non-patient specific immunotherapy candidates to efficiently target and kill cancer cells while sparing the surrounding tissue, which is critical in the treatment process.
Targeted immunotherapy candidates for the treatment of cancer are part of a growing field in cancer research, which holds great promise by harnessing the natural power of the immune system to fight disease. By eliciting a strong immune response, immunotherapies may slow the progress of the disease and increase overall survival - all with an improved safety profile compared to many traditional chemotherapies.
The Company’s lead development candidate, PROSTVAC®, is currently in a Phase 3 pivotal trial.